Natco Pharma Limited (NATCOPHARM) - Net Assets

Latest as of September 2025: Rs86.54 Billion INR ≈ $935.92 Million USD

Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has net assets worth Rs86.54 Billion INR (≈ $935.92 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs104.30 Billion ≈ $1.13 Billion USD) and total liabilities (Rs17.76 Billion ≈ $192.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Natco Pharma Limited to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs86.54 Billion
% of Total Assets	82.97%
Annual Growth Rate	23.4%
5-Year Change	84.61%
10-Year Change	484.1%
Growth Volatility	30.02

Natco Pharma Limited - Net Assets Trend (2005–2025)

This chart illustrates how Natco Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore how large is Natco Pharma Limited's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Natco Pharma Limited (2005–2025)

The table below shows the annual net assets of Natco Pharma Limited from 2005 to 2025. For live valuation and market cap data, see Natco Pharma Limited market cap and net worth.

Year	Net Assets	Change
2025-03-31	Rs76.12 Billion ≈ $823.24 Million	+30.06%
2024-03-31	Rs58.53 Billion ≈ $632.99 Million	-35.94%
2023-03-31	Rs91.37 Billion ≈ $988.18 Million	+114.31%
2022-03-31	Rs42.64 Billion ≈ $461.09 Million	+3.40%
2021-03-31	Rs41.23 Billion ≈ $445.93 Million	+8.95%
2020-03-31	Rs37.85 Billion ≈ $409.30 Million	+8.41%
2019-03-31	Rs34.91 Billion ≈ $377.54 Million	+13.49%
2018-03-31	Rs30.76 Billion ≈ $332.66 Million	+86.04%
2017-03-31	Rs16.53 Billion ≈ $178.81 Million	+26.87%
2016-03-31	Rs13.03 Billion ≈ $140.94 Million	+53.13%
2015-03-31	Rs8.51 Billion ≈ $92.04 Million	+16.15%
2014-03-31	Rs7.33 Billion ≈ $79.24 Million	+34.68%
2013-03-31	Rs5.44 Billion ≈ $58.84 Million	+15.25%
2012-03-31	Rs4.72 Billion ≈ $51.05 Million	+33.55%
2011-03-31	Rs3.53 Billion ≈ $38.23 Million	+13.78%
2010-03-31	Rs3.11 Billion ≈ $33.60 Million	+16.77%
2009-03-31	Rs2.66 Billion ≈ $28.77 Million	+18.21%
2008-03-31	Rs2.25 Billion ≈ $24.34 Million	+20.99%
2007-03-31	Rs1.86 Billion ≈ $20.12 Million	+20.93%
2006-03-31	Rs1.54 Billion ≈ $16.64 Million	+35.36%
2005-03-31	Rs1.14 Billion ≈ $12.29 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Natco Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 96107.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs62.47 Billion	82.12%
Common Stock	Rs358.00 Million	0.47%
Other Components	Rs13.25 Billion	17.41%
Total Equity	Rs76.07 Billion	100.00%

Natco Pharma Limited Competitors by Market Cap

The table below lists competitors of Natco Pharma Limited ranked by their market capitalization.

Company	Market Cap
Affle (India) Limited NSE:AFFLE	$2.16 Billion
Qingdao Huicheng Environmental Co Ltd SHE:300779	$2.16 Billion
Shanghai Hanbell Precise Machinery Co Ltd SHE:002158	$2.16 Billion
Anhui Anke BioTech Group SHE:300009	$2.16 Billion
Park Hotels & Resorts Inc NYSE:PK	$2.16 Billion
Blue Bird Corp NASDAQ:BLBD	$2.16 Billion
Bitdeer Technologies Group Class A Ordinary Shares NASDAQ:BTDR	$2.16 Billion
Banque Cantonale du Valais SW:WKBN	$2.16 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Natco Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 58,531,000,000 to 76,070,000,000, a change of 17,539,000,000 (30.0%).
Net income of 18,854,000,000 contributed positively to equity growth.
Dividend payments of 1,078,000,000 reduced retained earnings.
Share repurchases of 73,000,000 reduced equity.
New share issuances of 73,000,000 increased equity.
Other comprehensive income decreased equity by 1,497,000,000.
Other factors increased equity by 1,260,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs18.85 Billion	+24.79%
Dividends Paid	Rs1.08 Billion	-1.42%
Share Repurchases	Rs73.00 Million	-0.1%
Share Issuances	Rs73.00 Million	+0.1%
Other Comprehensive Income	Rs-1.50 Billion	-1.97%
Other Changes	Rs1.26 Billion	+1.66%
Total Change	Rs-	29.97%

Book Value vs Market Value Analysis

This analysis compares Natco Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.62x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 131.62x to 2.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs8.47	Rs1114.60	x
2006-03-31	Rs10.88	Rs1114.60	x
2007-03-31	Rs13.04	Rs1114.60	x
2008-03-31	Rs15.57	Rs1114.60	x
2009-03-31	Rs18.48	Rs1114.60	x
2010-03-31	Rs21.72	Rs1114.60	x
2011-03-31	Rs25.04	Rs1114.60	x
2012-03-31	Rs32.45	Rs1114.60	x
2013-03-31	Rs34.02	Rs1114.60	x
2014-03-31	Rs45.44	Rs1114.60	x
2015-03-31	Rs51.09	Rs1114.60	x
2016-03-31	Rs75.94	Rs1114.60	x
2017-03-31	Rs94.56	Rs1114.60	x
2018-03-31	Rs172.65	Rs1114.60	x
2019-03-31	Rs188.82	Rs1114.60	x
2020-03-31	Rs206.82	Rs1114.60	x
2021-03-31	Rs225.85	Rs1114.60	x
2022-03-31	Rs233.74	Rs1114.60	x
2023-03-31	Rs266.98	Rs1114.60	x
2024-03-31	Rs326.09	Rs1114.60	x
2025-03-31	Rs424.71	Rs1114.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Natco Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 24.79%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 42.54%
• Asset Turnover: 0.51x
• Equity Multiplier: 1.13x
Recent ROE (24.79%) is above the historical average (15.71%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	1.37%	1.01%	0.54x	2.53x	Rs-98.08 Million
2006	16.09%	14.16%	0.55x	2.08x	Rs90.09 Million
2007	16.90%	12.61%	0.69x	1.94x	Rs124.32 Million
2008	18.56%	12.36%	0.78x	1.92x	Rs186.86 Million
2009	16.97%	10.03%	0.85x	1.99x	Rs180.60 Million
2010	15.93%	11.31%	0.78x	1.80x	Rs181.44 Million
2011	15.18%	12.23%	0.62x	2.01x	Rs182.68 Million
2012	12.65%	11.46%	0.58x	1.92x	Rs124.88 Million
2013	13.47%	10.88%	0.61x	2.02x	Rs185.15 Million
2014	14.15%	13.90%	0.62x	1.65x	Rs301.47 Million
2015	15.91%	18.43%	0.53x	1.64x	Rs500.11 Million
2016	12.10%	15.07%	0.57x	1.40x	Rs272.67 Million
2017	29.47%	24.06%	0.87x	1.41x	Rs3.21 Billion
2018	22.66%	31.87%	0.59x	1.21x	Rs3.89 Billion
2019	18.47%	30.77%	0.49x	1.23x	Rs2.96 Billion
2020	12.21%	24.06%	0.42x	1.22x	Rs834.50 Million
2021	10.70%	21.44%	0.43x	1.16x	Rs287.40 Million
2022	3.99%	8.73%	0.38x	1.20x	Rs-2.56 Billion
2023	14.68%	26.41%	0.48x	1.16x	Rs2.28 Billion
2024	23.72%	34.69%	0.58x	1.18x	Rs8.03 Billion
2025	24.79%	42.54%	0.51x	1.13x	Rs11.25 Billion

Industry Comparison

This section compares Natco Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $35,979,469,852
Average return on equity (ROE) among peers: 17.85%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Natco Pharma Limited (NATCOPHARM)	Rs86.54 Billion	1.37%	0.21x	$2.16 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$1.14 Billion	5.77%	1.16x	$27.95 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.01 Billion	13.28%	2.64x	$390.72 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$790.23 Million
Abbott India Limited (ABBOTINDIA)	$1.88 Billion	54.31%	0.66x	$5.84 Billion
Ajanta Pharma Limited (AJANTPHARM)	$5.93 Billion	39.42%	0.60x	$3.92 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.20 Billion	-0.56%	3.88x	$925.81 Million
Alkem Laboratories Limited (ALKEM)	$49.85 Billion	12.66%	0.54x	$6.93 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.26 Billion	16.93%	0.29x	$179.06 Million
Alembic Pharmaceuticals Limited (APLLTD)	$31.90 Billion	25.98%	0.88x	$1.63 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$245.74 Billion	10.78%	0.38x	$8.64 Billion

About Natco Pharma Limited

NSE:NATCOPHARM India Drug Manufacturers - Specialty & Generic

Market Cap

$2.16 Billion

Rs199.64 Billion INR

Market Cap Rank

#5974 Global

#262 in India

Share Price

Rs1114.60

Change (1 day)

+1.72%

52-Week Range

Rs792.95 - Rs1123.70

All Time High

Rs1591.09